Filing Analysis
Z Squared Inc. entered into a Committed Equity Forward Purchase Agreement with LucentHash / Data Part Capital, providing the company access to up to $50 million in common stock funding over an 18-month period.
🚩 Red Flags
- Potential for significant dilution if the full $50 million is drawn, especially if the stock price drops toward the $3.00 absolute floor.
- The agreement involves a British Virgin Islands entity (Translucent Matter Inc.), which can sometimes complicate legal recourse.
📋 Key Facts
- Total commitment amount: up to $50,000,000 in common stock.
- Pricing: 95% of the 5-day volume-weighted average price (VWAP) per draw.
- Draw constraints: Minimum $50,000 and maximum $5,000,000 per draw; minimum 14 days between draws.
- Floor price: Initial floor of $5.00 per share, with an absolute floor of $3.00 per share.
- Commitment fee: $500,000 (1% of total) payable in five installments of $100,000 in shares.
- Lock-up: Shares are restricted with a nine-month contractual lock-up from issuance date.
- Exchange Cap: Issuances limited to 19.99% of outstanding shares unless shareholder approval is obtained.
Z Squared Inc. (formerly Coeptis Therapeutics Holdings, Inc.) filed an amendment to a previous 8-K to provide required audited financial statements and updated pro forma information following a reverse merger completed on April 24, 2026. The transaction is accounted for as a reverse acquisition where Z Squared OpCo Inc. is the accounting acquirer.
🚩 Red Flags
- Reverse merger structures in micro-cap companies can often be used to bypass traditional IPO scrutiny or facilitate rapid pivots in business models.
📋 Key Facts
- Merger completed on April 24, 2026, between CP Merger Sub, Inc. and Z Squared Inc. (Wyoming).
- The transaction is structured as a reverse acquisition under ASC 805-40.
- The filing provides audited financial statements for Z Squared OpCo Inc. for the fiscal years ended December 31, 2024 and 2025.
- Updated pro forma condensed combined financial information includes data as of March 31, 2026.
- The company has changed its name from Coeptis Therapeutics Holdings, Inc. to Z Squared Inc.
Z Squared Inc. (ZSQR) filed an 8-K on May 22, 2026 disclosing the resignation of Co-Chief Executive Officer and Director Michelle Burke, effective immediately. Burke's departure comes just 28 days after the company's business combination closed on April 24, 2026, raising questions about leadership stability in the critical post-merger integration period. David Halabu, who served as Co-CEO alongside Burke, will continue as sole CEO.
🚩 Red Flags
- Co-CEO departure just 28 days post-business combination close is highly unusual and may signal internal friction or strategic misalignment not disclosed under boilerplate 'no disagreement' language.
- Burke returning to Minting Dome, Inc. — a company holding an active Master Services Agreement with Z Squared — creates a potential related-party conflict of interest going forward.
- Board vacancy created by Burke's resignation has not been filled, creating a governance gap in the immediate post-merger period.
- Company underwent a full name and ticker change (Coeptis Therapeutics → Z Squared Inc., COEP → ZSQR), suggesting a significant and rapid strategic transformation with limited public track record under new identity.
- Sole remaining CEO's background is primarily in trading and real estate — not obviously aligned with the company's apparent operational focus — raising questions about strategic direction.
📋 Key Facts
- Michelle Burke resigned as Co-CEO and Director effective May 22, 2026 — only 28 days after the business combination closed on April 24, 2026.
- Burke is returning to Minting Dome, Inc., with which the Company maintains an existing Master Services Agreement.
- David Halabu (age 50) transitions from Co-CEO to sole CEO effective May 22, 2026.
- Halabu has served as CEO of Z Squared OpCo Inc. (wholly-owned operating subsidiary) since June 2024.
- No successor has been appointed to fill the Board vacancy created by Burke's resignation.
- Burke's resignation was stated to not be the result of any disagreement with the Company on operations, policies, or practices.
- No changes were made to Halabu's compensation arrangements.
- The Company is formerly known as Coeptis Therapeutics Holdings, Inc., now trading as ZSQR on Nasdaq Global Market.
- Halabu's background is in trading, real estate, and alternative investments — not traditional pharma/biotech.
Z Squared Inc. announced its Phase 1 plan to reach 100 megawatts (MW) of AI-ready infrastructure capacity dedicated to inference workloads. The announcement was made via a press release on May 19, 2026, and furnished under Item 7.01.
🚩 Red Flags
- Potential organizational confusion or recent restructuring, as the filing header references 'COEPTIS THERAPEUTICS HOLDINGS, INC.' and ticker 'COEP', while the body of the filing refers to 'Z Squared Inc.' and ticker 'ZSQR'.
📋 Key Facts
- Z Squared Inc. announced a Phase 1 plan to achieve 100 MW of AI-ready infrastructure capacity.
- The infrastructure capacity is specifically targeted for AI inference workloads.
- The press release was dated May 19, 2026, and furnished as Exhibit 99.1.
- The report was signed by Co-CEO David Halabu on May 20, 2026.
Z Squared Inc. (formerly Coeptis Therapeutics) entered into a binding LOI to acquire Skycore Digital LLC for up to $22 million in preferred stock and announced a total turnover of its executive leadership and board following a merger. The company also disclosed multiple equity-based compensation agreements with various consulting and investor relations firms.
🚩 Red Flags
- Complete turnover of the Board of Directors and executive management team in a single event.
- Significant pivot in business model implied by the acquisition of data center assets (Skycore) by a company formerly named Coeptis Therapeutics.
- High volume of equity-based compensation for investor relations and marketing services, which can be dilutive and sometimes associated with stock promotion.
- Multiple 8-K items (1.01, 3.02, 5.02) filed simultaneously indicating complex corporate restructuring.
📋 Key Facts
- Binding LOI to acquire 100% of Skycore Digital LLC for an initial $18 million in Series B Convertible Preferred Stock, potentially increasing to $22 million based on power capacity milestones.
- The Series B Preferred Stock features an 8% cash or 10% PIK dividend and a mandatory redemption on the seventh anniversary of closing.
- Complete resignation of all prior directors and officers effective April 27, 2026, following a merger with Z Squared Opco, Inc.
- Appointment of David Halabu and Michelle Burke as Co-CEOs and Brian Cogley as CFO.
- Issuance of 200,000 shares to Group 10 Holdings and up to 566,000 shares to Moneta Advisory Partners for consulting and IR services.
- Additional share issuances for IR services to MZHCI, LLC ($100,000 value) and Retail Sparks ($75,000 value).
Coeptis Therapeutics Holdings, Inc. completed a reverse merger with Z Squared Inc. on April 24, 2026, resulting in a change of control, a name change to Z Squared Inc., and a ticker change to ZSQR. The transaction involved a complete turnover of the board and executive management, and the spin-off of legacy biopharmaceutical assets to pre-merger shareholders.
🚩 Red Flags
- Reverse merger structure, which is a common method for private companies to bypass the traditional IPO process.
- Complete turnover of management and the board of directors.
- Complex pre-merger asset reorganization and pro-rata dividend distribution to legacy shareholders.
- Significant dilution for legacy COEP shareholders, who now hold a minority stake in the new entity.
📋 Key Facts
- Merger completed on April 24, 2026, with Z Squared Inc. (Wyoming) becoming a wholly owned subsidiary of the registrant.
- The registrant issued 43,877,497 shares of common stock to Z Squared stockholders as merger consideration.
- Total post-merger shares outstanding are 51,431,493, with Z Squared stockholders owning approximately 85% of the company.
- The company changed its name to Z Squared Inc. and its ticker symbol from 'COEP' to 'ZSQR' effective April 27, 2026.
- All previous directors and officers resigned, replaced by a new five-member board and executive team led by CEO David Halabu.
- Legacy biopharmaceutical assets (excluding GEAR Therapeutics, Inc.) were reorganized into Coeptis Holdings, Inc. (CHI) and distributed as a dividend to pre-merger stockholders.
- The transaction is accounted for as a reverse merger, with Z Squared OpCo Inc. as the accounting acquirer.
Coeptis Therapeutics Holdings, Inc. issued a press release providing supplemental information regarding its business combination with Z Squared, Inc. (NASDAQ: ZSQR). The update also includes details on a pro rata dividend distribution of Coeptis's pre-combination biopharmaceutical business to its shareholders.
📋 Key Facts
- The company is undergoing a business combination with Z Squared, Inc. (NASDAQ: ZSQR).
- A pro rata dividend distribution is planned for Coeptis's pre-business combination biopharmaceutical assets.
- The press release was issued on April 27, 2026, to supplement previous disclosures.
- The filing was signed by Brian Cogley, Chief Financial Officer.
Coeptis Therapeutics Holdings, Inc. announced the successful completion of its business combination with Z Squared Inc. The company will transition its ticker symbol from 'COEP' to 'ZSQR' and expects to begin trading on the Nasdaq Global Market on April 27, 2026.
📋 Key Facts
- Completed business combination with Z Squared Inc. on April 24, 2026.
- Ticker symbol change from 'COEP' to 'ZSQR' effective April 27, 2026.
- The company's shares will trade on the Nasdaq Global Market.
- New CUSIP for the common stock is 98878K108.
Coeptis Therapeutics announced that Nasdaq has conditionally approved the listing of the post-merger company's common stock on the Nasdaq Global Market. The approval is contingent upon the closing of the company's merger with Z Squared Inc., at which point the ticker will change from 'COEP' to 'ZSQR'.
📋 Key Facts
- Nasdaq approved the listing of the post-merger entity on the Nasdaq Global Market.
- The new ticker symbol will be 'ZSQR' following the merger with Z Squared Inc.
- The approval is subject to customary conditions and the successful closing of the merger.
- The announcement was made via press release on April 7, 2026.
- The company's common stock is currently listed on the Nasdaq Capital Market.